Study guide

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders

Key Takeaways Explain This Topic AI

Barrett's oesophagus is intestinal metaplasia with goblet cells; high-grade dysplasia is managed by endoscopic resection and radiofrequency ablation rather than surveillance.

Achalasia shows absent peristalsis with failure of lower oesophageal sphincter relaxation on manometry and a bird's beak appearance on barium swallow.

Dysphagia to solids and liquids simultaneously from onset suggests a motility disorder, whereas progressive dysphagia to solids first suggests a mechanical stricture or carcinoma.

Last updated: September 2026

Upper gastrointestinal pathology forms a core component of the MRCP(UK) Part 1 curriculum. Candidates must master the physiological mechanisms of gastro-oesophageal reflux, endoscopic surveillance criteria in premalignant lesions, manometric classification of motility disorders, the pathophysiology and eradication regimens of Helicobacter pylori , and the biochemical workup of neuroendocrine gastrinomas.

  • 1. Gastro-Oesophageal Reflux Disease (GORD) & Barrett's Oesophagus
  • Pathophysiology of GORD

Gastro-oesophageal reflux disease (GORD) develops when the antireflux barrier at the esophagogastric junction is compromised, allowing acidic gastric contents and bile acids to retrograde into the oesophagus. Key pathophysiological drivers include:

Transient Lower Oesophageal Sphincter Relaxations (TLESRs): Abrupt, vagally mediated reflex relaxations of the lower oesophageal sphincter (LOS) unassociated with swallowing, accounting for >70% of physiological and pathological reflux episodes.

Hiatus Hernia: Herniation of elements of the abdominal cavity through the oesophageal hiatus into the mediastinum. In sliding hiatus hernia (Type I, ~95%) , the gastro-oesophageal junction (GOJ) slides upward above the diaphragmatic crus, uncoupling the intrinsic LOS smooth muscle from the extrinsic diaphragmatic sphincter ("pinchcock" mechanism), blunting acid clearance and creating an acid pocket. In rolling / paraoesophageal hernia (Type II/III) , the fundus herniates alongside the oesophagus while the GOJ remains anchored; this carries a high risk of strangulation, volvulus, and gastric infarction, frequently demanding elective surgical repair.

Impaired Oesophageal Clearance & Delayed Gastric Emptying: Defective secondary peristalsis, hyposecretion of salivary bicarbonate, and gastroparesis exacerbate mucosal contact time with noxious hydrochloric acid, pepsin, and conjugated bile salts.

Clinical Presentation & Diagnostic Strategy

Typical Symptoms: Retrosternal burning pyrosis (heartburn) radiating toward the neck, acid regurgitation, and water brash (reflex salivary hypersecretion triggered by oesophageal acidification).

Extra-Oesophageal (Atypical) Manifestations: Chronic dry cough, nocturnal asthma exacerbations (microaspiration or vagally mediated bronchospasm), reflux laryngitis with hoarseness, globus pharyngeus, and severe dental enamel erosion.

Endoscopy Indications (NICE Guidelines): Upper endoscopy is not required for uncomplicated reflux in young patients responding to empirical proton pump inhibitor (PPI) therapy. Urgent 2-week-wait endoscopy is mandated in the presence of "alarm features": dysphagia (any age), unintentional weight loss , persistent vomiting , epigastric mass , gastrointestinal bleeding , or age >=55 with new-onset unexplained dyspepsia .

Ambulatory 24-Hour Oesophageal pH and Impedance Monitoring: Regarded as the diagnostic gold standard for confirming pathological acid reflux in patients with endoscopy-negative reflux disease (NERD) or those considered for antireflux surgery (laparoscopic Nissen fundoplication). A DeMeester score >14.72 or acid exposure time (AET) >6% establishes pathological acid exposure.

Barrett's Oesophagus

Barrett's oesophagus is defined histopathologically by the replacement of the normal stratified squamous epithelium of the distal oesophagus by specialized columnar epithelium containing mucin-secreting goblet cells (intestinal metaplasia) , extending >=1 cm proximal to the anatomical gastro-oesophageal junction.

Malignant Risk: Barrett's oesophagus represents the single recognized precursor lesion for oesophageal adenocarcinoma (OAC). The baseline risk of malignant progression in non-dysplastic Barrett's is approximately 0.1–0.3% per patient-year, escalating dramatically when dysplasia develops.

Endoscopic Staging — The Prague Classification: Evaluates the extent of Barrett's mucosa above the proximal margins of the gastric folds:

C Criteria: Circumferential extent of columnar epithelium in centimetres.

M Criteria: Maximum extent of columnar epithelium (including tongues/islands) in centimetres (e.g., C3M5 indicates 3 cm circumferential involvement with a maximum tongue length of 5 cm).

Surveillance & Management (British Society of Gastroenterology [BSG] Guidelines):

Non-Dysplastic Barrett's Oesophagus: Surveillance gastroscopy utilizes high-definition white-light endoscopy with the Seattle protocol (targeted biopsies of mucosal irregularities plus four-quadrant random biopsies taken every 2 cm throughout the Barrett's segment):

Segment length <3 cm (short-segment): Surveillance gastroscopy every 3–5 years .

Segment length >=3 cm (long-segment): Surveillance gastroscopy every 2–3 years .

Indefinite for Dysplasia: Optimize acid suppression (high-dose PPI BD) for 3–6 months to resolve active mucosal inflammation, followed by repeat endoscopy with Seattle protocol biopsies.

Low-Grade Dysplasia (LGD): Must be independently confirmed by two gastrointestinal expert pathologists. Options comprise either endoscopic radiofrequency ablation (RFA) or intensive 6-monthly endoscopic surveillance.

High-Grade Dysplasia (HGD) & Intramucosal Carcinoma (T1a): High risk of progression to invasive adenocarcinoma (>10% per year). Managed via endoscopic mucosal resection (EMR) for any visible discrete nodule or elevated lesion to ensure accurate histological staging, followed by radiofrequency ablation (RFA) to eradicate the residual flat Barrett's mucosa. Oesophagectomy is now reserved for submucosal invasive adenocarcinoma (T1b) or refractory multifocal disease.

  • 2. Oesophageal Motility Disorders
  • Achalasia

Achalasia is a primary neurodegenerative motility disorder characterized by failure of the lower oesophageal sphincter (LOS) to relax upon deglutition, accompanied by loss of coordinated propulsive peristalsis within the tubular oesophagus.

Pathophysiology: Chronic inflammation and autoimmune-mediated destruction of postganglionic inhibitory parasympathetic ganglion cells in the myenteric (Auerbach) plexus of the oesophageal muscularis propria. Loss of inhibitory neurotransmitters ( nitric oxide [NO] and vasoactive intestinal peptide [VIP] ) leads to unopposed cholinergic stimulation, elevating basal LOS tone and abolishing receptive sphincter relaxation.

Clinical Features: Insidious, slowly progressive dysphagia to both solids and liquids from onset (unlike mechanical obstruction where solid dysphagia precedes liquids), effortless regurgitation of undigested, non-acidic food and saliva, nocturnal aspiration, retrosternal chest discomfort, and progressive weight loss.

Diagnostic Evaluation:

Chest Radiograph: May show an absent gastric air bubble, a dilated fluid-filled mediastinum, and a widened mediastinal contour with an air-fluid level.

Barium Swallow: Smooth, tapered, conical symmetric narrowing at the gastro-oesophageal junction with massive dilatation and tortuosity of the proximal oesophagus—the classic "bird's beak" or "rat-tail" sign.

Upper GI Endoscopy: Essential to exclude pseudoachalasia (secondary achalasia) , in which gastric cardia or gastro-oesophageal junction adenocarcinoma, lymphoma, or metastatic disease infiltrates the myenteric plexus, mimicking achalasia. Red-flag clues for pseudoachalasia include age >60 years, abrupt symptom duration (<6 months), and profound, rapid weight loss.

High-Resolution Manometry (HRM): Gold standard diagnostic investigation. Characterized per the Chicago Classification into three distinct subtypes, all requiring an elevated Integrated Relaxation Pressure ( IRP >15 mmHg ) and 100% failed peristalsis:

Achalasia Subtype Manometric Pattern Clinical Response to Treatment

Type I (Classic) 100% failed peristalsis; negligible oesophageal pressurization Moderate response to pneumatic dilatation or Heller myotomy

Type II (Pan-oesophageal Pressurization) 100% failed peristalsis; >=20% of swallows exhibit pan-oesophageal pressurization Best clinical prognosis ; excellent response to dilatation or myotomy

Type III (Spastic) 100% failed peristalsis; >=20% of swallows demonstrate premature, spastic contractions Poor response to standard dilatation; Peroral Endoscopic Myotomy (POEM) is treatment of choice

Therapeutic Interventions:

Pneumatic Balloon Dilatation: Forceful disruption of the LOS circular muscle fibres using graded large-diameter balloons (30, 35, 40 mm). High initial clinical success (~80–90%), but carries a 2–3% risk of oesophageal perforation.

Laparoscopic Heller Myotomy: Surgical division of the circular muscle fibres of the distal oesophagus and proximal stomach, coupled with an antireflux partial fundoplication (Dor or Toupet procedure) to prevent postoperative reflux.

Peroral Endoscopic Myotomy (POEM): Advanced, minimally invasive endoscopic submucosal technique that creates a submucosal tunnel to dissect the inner circular muscular layer. Particularly effective in Type III spastic achalasia where a long myotomy is required.

Botulinum Toxin A Injection: Endoscopic injection into the four quadrants of the LOS blocks presynaptic acetylcholine release. Reserved strictly for frail, elderly individuals or patients unfit for definitive surgical or balloon interventions due to transient efficacy (symptoms recur in >50% within 6–12 months).

Pharmacological Therapy: Oral calcium channel blockers (nifedipine) or sublingual isosorbide dinitrate relax smooth muscle, serving solely as temporary bridges before intervention.

Diffuse Oesophageal Spasm & Other Motility Disorders

Diffuse Oesophageal Spasm (Distal Oesophageal Spasm): Uncoordinated, simultaneous, non-propulsive contractions of the distal smooth-muscle oesophagus with normal lower oesophageal sphincter relaxation. Manifests with severe, episodic, gripping retrosternal chest pain (often provoked by hot or cold liquids, mimicking acute coronary syndrome) and intermittent dysphagia. Barium swallow classically shows a "corkscrew" or "rosary bead" oesophagus. High-resolution manometry reveals normal IRP with >=20% premature contractions (distal latency <4.5 seconds). Managed with calcium channel blockers (diltiazem), nitrates, tricyclic antidepressants (neuropathic pain modulation), or sildenafil.

Systemic Sclerosis (Scleroderma Oesophagus): Progressive smooth muscle atrophy, collagen deposition, and fibrous replacement of the muscularis propria in the lower two-thirds of the oesophagus. Leads to complete aperistalsis and profound hypotonia of the lower oesophageal sphincter (a wide-open, patulous sphincter). Results in severe, intractable gastro-oesophageal reflux, recurrent peptic strictures, and high risk of Barrett's oesophagus. High-resolution manometry shows normal or low resting IRP with completely absent peristalsis.